Astrazeneca annual return on equity
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Return on Equity (ROE) Growth & History (AZN)
Astrazeneca's return on equity was 22.88% for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 22.88% | +5.26 pp |
| 2024 | 2024-12-31 | 17.62% | +1.97 pp |
| 2023 | 2023-12-31 | 15.65% | +7.02 pp |
| 2022 | 2022-12-31 | 8.63% | +8.21 pp |
| 2021 | 2021-12-31 | 0.42% | −21.45 pp |
| 2020 | 2020-12-31 | 21.87% | +12.28 pp |
| 2019 | 2019-12-31 | 9.59% | −5.36 pp |
| 2018 | 2018-12-31 | 14.95% | −4.29 pp |
| 2017 | 2017-12-31 | 19.24% | −1.19 pp |
| 2016 | 2016-12-31 | 20.43% | — |
Astrazeneca quarterly return on equity
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.14% | −0.59 pp |
| Q1 2026 | 2026-03-31 | 6.42% | — |
| Q4 2025 | 2025-12-31 | 4.92% | — |
| Q3 2025 | 2025-09-30 | 5.59% | — |
| Q2 2025 | 2025-06-30 | 5.73% | +0.82 pp |
| Q2 2024 | 2024-06-30 | 4.90% | +0.01 pp |
| Q2 2023 | 2023-06-30 | 4.89% | +3.93 pp |
| Q2 2022 | 2022-06-30 | 0.96% | −2.56 pp |
| Q2 2021 | 2021-06-30 | 3.51% | −2.30 pp |
| Q2 2020 | 2020-06-30 | 5.82% | +5.00 pp |
| Q2 2019 | 2019-06-30 | 0.82% | −1.49 pp |
| Q2 2018 | 2018-06-30 | 2.31% | — |
Astrazeneca return on equity trends
Over the last five fiscal years, Astrazeneca's return on equity increased from 21.87% to 22.88%, a change of +1.01 percentage points. The latest reported quarter, Q2 2026, shows 5.14%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...